Zitter Ryan, Chugh Rishi Man, Saha Subhrajit
Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Cancers (Basel). 2022 Jun 18;14(12):3006. doi: 10.3390/cancers14123006.
The field of cancer research is famous for its incremental steps in improving therapy. The consistent but slow rate of improvement is greatly due to its meticulous use of consistent cancer biology models. However, as we enter an era of increasingly personalized cancer care, including chemo and radiotherapy, our cancer models must be equally able to be applied to all individuals. Patient-derived organoid (PDO) and organ-in-chip (OIC) models based on the micro-physiological bioengineered platform have already been considered key components for preclinical and translational studies. Accounting for patient variability is one of the greatest challenges in the crossover from preclinical development to clinical trials and patient derived organoids may offer a steppingstone between the two. In this review, we highlight how incorporating PDO's and OIC's into the development of cancer therapy promises to increase the efficiency of our therapeutics.
癌症研究领域以其在改善治疗方面的渐进式进展而闻名。改善速度持续但缓慢，这在很大程度上归因于其对一致的癌症生物学模型的精心运用。然而，随着我们进入一个包括化疗和放疗在内的癌症个性化治疗日益普及的时代，我们的癌症模型必须同样能够应用于所有个体。基于微生理生物工程平台的患者来源类器官（PDO）和芯片器官（OIC）模型已被视为临床前和转化研究的关键组成部分。在从临床前开发过渡到临床试验的过程中，考虑患者变异性是最大的挑战之一，而患者来源类器官可能为两者之间提供一个垫脚石。在这篇综述中，我们强调将PDO和OIC纳入癌症治疗开发有望提高我们治疗方法的效率。
